... repeat protein (Nesprin) 1 encoded by SYNE1 , crucially regulates the morphology and functions of the cell. Mutations in the SYNE1 gene are associated with various diseases; however, their significance in renal cell carcinoma (RCC) remains unknown. In this study, we have investigated the association...

... in malignant tumors. A nectin-4-directed antibody drug conjugate, enfortumab vedotin-ejf, has recently been approved for treatment in urothelial cancer and is currently under investigation in other tumor entities such as breast, lung, and prostate cancer. In non-clear cell renal cell carcinoma (RCC), vascular...

...Alexander Shieh; Steven Y. Cen; Bino A. Varghese; Darryl Hwang; Xiaomeng Lei; Ali Setayesh; Imran Siddiqi; Manju Aron; Anishka Dsouza; Inderbir S. Gill; William Wallace; Vinay Duddalwar Introduction: Renal cell carcinoma (RCC) is the ninth most common cancer worldwide, with clear cell RCC (ccRCC...

... in renal cell carcinoma (RCC), especially in non-clear cell RCC, is still unclear. Aim: The aim of the study was to evaluate the prognostic impact of Gas6 expression in a large cohort of patients with chromophobe RCC (chRCC). Material and Methods: Patients who underwent renal surgery due to chRCC were...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Renal cell carcinoma Trophoblast cell surface antigen 2 Chromophobe histology...

... in renal cell carcinoma (RCC). Methods: The expression of BUB1B was determined using immunohistochemistry and bioinformatics analysis in RCC. The effects of BUB1B knockdown on cell growth and invasion were evaluated. We analyzed the interaction between BUB1B, cancer stem cell markers, p53, and PD-L1 in RCC...

...-programmed cell death protein 1 (PD-1) monoclonal antibody – for renal cell carcinoma (RCC) are 3 mg/kg and a 240-mg flat dose, despite efficacy shown at lower doses in earlier CheckMate trials. In view of financial constraints, the minimum dose of nivolumab required for efficacy remains a critical area...

...Kengo Horie; Kyojiro Kawakami; Yasunori Fujita; Yoko Matsuda; Tomio Arai; Natsuko Suzui; Tatsuhiko Miyazaki; Takuya Koie; Kosuke Mizutani; Masafumi Ito Background: There has been no clinically useful diagnostic or prognostic biomarker for renal cell carcinoma (RCC). Serum γ-glutamyltransferase (GGT...

..., is a microtubule protein. Several studies have shown that overexpression of TUBB3 is linked to poor prognosis and is involved in taxane resistance in some cancers. Objective: The aim of this study was to analyze the expression and function of TUBB3 in clear cell renal cell carcinoma (ccRCC). Methods...

... mononuclear cells (PBMC) and lymphocytes in humans including renal cell carcinoma (RCC) patients. Theoretically, various conditions and diseases such as cancer could also affect the expression of RTKs on PBMC. The main goal of this pilot study was to assess the presence of the expression of major RTKs...

...Andrey Soares; Manuel C. Maia; Fernando Vidigal; Fernando Sabino Marques Monteiro Cytoreductive nephrectomy (CN) followed by systemic therapy had been considered the standard of care for metastatic renal cell carcinoma (mRCC) patients since two clinical trials established its role during...

... and drug resistance in some cancers. However, the expression and biological role of miR-130b in renal cell carcinoma (RCC) remain poorly understood. This study aimed to examine the expression and functional role of miR-130b and to analyze the association between miR-130b and sunitinib resistance in RCC...

...: Pancreatic metastases (PM) from renal cell carcinoma (RCC) have been associated with long-term survival. The aim of this study was to evaluate the outcome of RCC patients with multiple glandular metastases (MGM) treated with targeted therapies (TTs). Methods: Sixty-four MGM patients treated between 1993...

... to crossover in oncology clinical trials. Methods: An indirect comparison was conducted between pazopanib and sunitinib in advanced renal cell carcinoma. Statistical adjustment methods were used to estimate the true comparative effectiveness of these treatments. Recently, a head-to-head trial comparing...

... of potential prognostic variables. A continuous model that incorporates both categorical and continuous variables and does not combine subgroups of patients with potentially heterogeneous outcomes would be of additional value to clinicians. Renal cell carcinoma (RCC) is the most common form of kidney...

...Ilya Tsimafeyeu; Gennady Bratslavsky Dysregulation of fibroblast growth factor (FGF) signaling in renal cell carcinoma is now well understood, and it is becoming increasingly likely that certain tumors become dependent on an activation of this pathway for their growth and survival. Dissecting...

...; Subramanian Hariharan; Barbara Capaccetti; Camillo Porta Objectives: Patients with metastatic renal cell carcinoma (mRCC) received sunitinib in a global expanded-access program (EAP). Here, we report the efficacy and safety results for the EAP subpopulation in Italy. Methods: Patients ≥18 years old...

... in metastatic renal cell carcinoma (mRCC) patients treated with targeted therapies (TTs). Subjects and Methods: All patients who underwent Nx and at least 1 TT were considered. The patients were divided into two groups based on time from Nx [>1 year (Nx >1) and <1 year (Nx <1)] and a third group...

... renal cell carcinoma (RCC) from a randomized, double-blind, placebo-controlled phase III study (VEG105192/NCT00334282). Methods: Patients received pazopanib 800 mg/day. The primary endpoint was the safety and tolerability of pazopanib treatment. Secondary endpoints included response rate per Response...

... trials, including telephone reminders and open-trial designs [ 3 ]. We felt that it is time to take a snapshot of the recruitment practice in our hospital in recent years, with a specific focus on renal-cell carcinoma, a disease that underwent an unprecedented change in treatment paradigm...